Success Metrics

Active Trials
4(80%)

Phase Distribution

Ph phase_2
3
60%
Ph phase_4
1
20%
Ph phase_3
1
20%

Phase Distribution

0

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Other(1)

Detailed Status

Active, not recruiting3
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
4
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 23 (60.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)

Trials by Status

unknown120%
active_not_recruiting360%
recruiting120%

Recent Activity

4 active trials
Showing 5 of 5
active_not_recruitingphase_2

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

NCT04290793
active_not_recruitingphase_3

Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

NCT02455141
active_not_recruitingphase_2

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

NCT02299999
recruitingphase_4

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

NCT06217185
unknownphase_2

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

NCT04760431

Clinical Trials (5)

Showing 5 of 5 trials
NCT04290793Phase 2

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Active Not Recruiting
NCT02455141Phase 3

Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

Active Not Recruiting
NCT02299999Phase 2

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active Not Recruiting
NCT06217185Phase 4

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Recruiting
NCT04760431Phase 2

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5